FMP
Merck & Co., Inc.
MRK
NYSE
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
84.71 USD
1.52 (1.79%)
Historical Prices
From:
To:
About
ceo
Mr. Robert M. Davis J.D.
sector
Healthcare
industry
Drug Manufacturers - General
website
https://www.merck.comexchange
NYSE
Description
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals,...
CIK
0000310158
ISIN
US58933Y1055
CUSIP
58933Y105
Address
2000 Galloping Hill Road
Phone
908 740 4000
Country
US
Employee
73,000
IPO Date
Jan 13, 1978
Financial Statement
Earnings
MRK Financial Summary
CIK
0000310158
Exchange
NYSE
Industry
Drug Manufacturers -...
Sector
Healthcare
CUSIP
58933Y105
ISIN
US58933Y1055
Country
US
Price
84.71
Beta
0.42
Volume Avg.
18.23M
Market Cap
213.16B
Shares
-
52-Week
75.93-134.63
DCF
235.16
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
12.31
P/B
-
Website
https://www.merck.com
Upgrades and Downgrades
Rating Distribution
TheFly
5 days ago
Apr 25, 2025
Market Perform
Market Perform
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MRK News
Parth Sanghvi
2 days ago
Merck KGaA to Acquire SpringWorks Therapeutics in $3.9 Billi...
Strategic Acquisition to Expand Oncology Portfolio Deal Overview: German healthcare and materials giant Merck KGaA (NSE: PROR) announced on Monday it will acquire U.S. biotech firm SpringWorks Therapeutics for $47 per share in cash, representing a total equity value of $3.9 billion. After adjusting for SpringWorks' cash holdings, the enterprise value stands at approximately $3.4 billion (3.0 billion euros). Funding and Financial Impact: The acquisition will be financed through a combinat...
Stuart Mooney
Feb 5, 2025
Goldman Sachs Maintains "Buy" Rating on Merck (NYSE:MRK)
On February 5, 2025, Goldman Sachs reaffirmed its "Buy" rating for Merck (NYSE:MRK), maintaining its previous grade. At the time of this announcement, the stock was priced at approximately $89.63. Despite investor concerns over weak guidance, analysts continue to support Merck, as reported by Benzinga. Merck, a leading pharmaceutical company based in Rahway, is recognized for its strong dividend payouts, making it a top choice for income investors, as highlighted by Zacks Investment Research. M...
Davit Kirakosyan
Feb 4, 2025
Merck Shares Plunge 8% as Weak Guidance Overshadows Strong R...
Merck & Co (NYSE:MRK) saw its stock sink over 8% in pre-market today after delivering mixed fourth-quarter results, with earnings missing expectations, revenue exceeding forecasts, and full-year guidance coming in below analyst estimates. For Q4, the pharmaceutical giant reported adjusted earnings per share (EPS) of $1.72, falling short of the $1.81 consensus estimate. However, revenue climbed 7% year-over-year to $15.6 billion, surpassing projections of $15.47 billion. Excluding foreign exchang...
Andrew Wynn
Sep 9, 2024
Today's Top Stock Pick: Merck & Co., Inc. (MRK)
Today's top stock pick, Merck & Co., Inc. (NYSE:MRK), is a standout in the pharmaceutical industry, known for its innovative drug development and global presence. Merck's commitment to research and development in areas like oncology and vaccines positions it well against competitors, offering a unique investment opportunity. The company's recent performance, growth potential, and financial health are key factors that make MRK an intriguing choice for investors. MRK has seen a modest monthly gai...
Zacks Investment Research
Aug 26, 2024
The Zacks Analyst Blog Costco, Merck & Co., Linde, Hamilton ...
Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of Distinction are included in this Analyst Blog.
CNBC International TV
Aug 25, 2024
Fertility-related stocks are becoming more attractive, Barcl...
CNBC's Silvia Amaro takes a look at why investors are growing more interested in fertility-related stocks.
Zacks Investment Research
Aug 23, 2024
Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?
Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.
Zacks Investment Research
Aug 23, 2024
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a...
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
